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Abstract
The role of radiotherapy for local control of
marginally resected, unresectable, and recurrent
giant cell tumors of bone (GCToB) has not been
well defined. The number of patients affected by
this rare disease is low. We present a series of 58
patients  with  biopsy  proven  GCToB  who  were
treated with radiation therapy. A retrospective
review of the role of radiotherapy in the treat-
ment of GCToB was conducted in participating
institutions  of  the  Rare  Cancer  Network.
Eligibility criteria consisted of the use of radio-
therapy  for  marginally  resected,  unresectable,
and recurrent GCToB. Fifty-eight patients with
biopsy proven GCToB were analyzed from 9 par-
ticipating North American and European institu-
tions. Forty-five patients had a primary tumor
and 13 patients had a recurrent tumor. Median
radiation dose was 50 Gy in a median of 25 frac-
tions. Indication for radiation therapy was mar-
ginal  resection  in  33  patients,  unresectable
tumor in 13 patients, recurrence in 9 patients
and palliation in 2 patients. Median tumor size
was  7.0  cm.  A  significant  proportion  of  the
tumors involved critical structures. Median fol-
low-up was 8.0 years. Five year local control was
85% . Of the 7 local failures, 3 were treated suc-
cessfully with salvage surgery. All patients who
received palliation achieved symptom relief. Five
year  overall  survival  was  94%.  None  of  the
patients experienced grade 3 or higher acute tox-
icity. This study reports a large published experi-
ence in the treatment of GCToB with radiothera-
py. Radiotherapy can provide excellent local con-
trol  for  incompletely  resected,  unresectable  or
recurrent GCToB with acceptable morbidity.
Introduction
Giant cell tumors of the bone compose 5% of all
bone tumors. They have a slight female predomi-
nance and are the most common during the third
and  fourth  decade  of  life.  Histologically  these
tumors  exhibit  mononuclear  stromal  cells  and
multinucleated giant cells. It is believed that these
stromal cells promote the growth of multinucleat-
ed osteoclast-like cells.1,2Despite their histology, a
small portion of these tumors develop hematoge-
nous metastasis. These patients, however, can still
have long survival due to the indolent nature of
this  disease.  As  these  tumors  can  be  locally
aggressive, local control is very important. Surgery,
typically consisting of en bloc resection with nega-
tive margins, remains the most important treat-
ment modality. However, in many instances, these
tumors occur in places not amenable to complete
surgical  resection.  The  role  of  radiotherapy
remains to be defined.3-5We report the results of a
large  multi-institutional  experience  evaluating
the role of radiotherapy for marginally resected,
unresectable and recurrent GCToB.
Materials and Methods
A retrospective review of the role of radio-
therapy  in  58  consecutively  treated  patients
with GCToB was conducted in 9 participating
institutions  of  the  Rare  Cancer  Network.
Eligibility  criteria  consisted  of  the  role  of
radiotherapy  for  marginally  resected,  unre-
sectable  or  recurrent  GCToB.  Cancers  that
were  deemed  unresectable  by  the  surgeon
were due to location adjacent to critical struc-
tures  that  would  compromise  function.
Primary study endpoints included local failure
(LF) and overall survival (OS) rates. Secondary
endpoints included toxicity, secondary malig-
nancy occurrence, and prognostic factors. The
Kaplan-Meier  actuarial  method  was  used  to
calculate  survivals  and  tumor  failures.  Log-
Rank testing was used to determine prognostic
factors. This study was approved by the Mayo
Foundation Institutional Review Board and at
each participating site independently.
This  study  was  approved  by  the  Mayo
Foundation Institutional Review Board and at
each participating site independently.
Results
Patient and tumor characteristics
A  total  of  58  patients  with  biopsy  proven
GCToB  of  histology  ICD-0-3-92501  and  92503
were  analyzed  from  European  and  North
American academic centers (Table 1). Forty-five
patients had a newly diagnosed GCToB with a
median number of tumors at presentation of 1
(range 1 to 2). Thirteen patients had a recur-
rent tumor with a median number of localiza-
tions at presentation of 1 (range 1 to 4).
Median age was 31 years (range 12 to 84).
Median tumor size was 7 cm (range 2 to 15
cm).  A  significant  portion  of  the  tumors
involved the long bones of the lower limb. In
55%  of  the  cases,  critical  structures  were
involved, of which the sacral plexus was the
most common one. 
Treatment characteristics 
Thirteen  patients  had  an  unresectable
tumor and therefore did not have surgery as a
component of their treatment (Table 2). Of the
patients who had surgery, 30 patients had a R1
resection and 26 patients had a R2 resection.
R1 resection was defined as microscopic dis-
ease left behind and R2 defined as gross dis-
ease left behind at the time of surgery. Out of
the 26 patients who underwent a R2 resection,
the largest diameter of the residual tumor was
known for 14 patients. The median diameter of
residual disease after R2 resection was 9.5 cm
(range 2.0 to 14.0 cm). 
All patients received radiation between 1976
to  2007.  Indications  for  radiotherapy  were
recurrent  GCToB  after  prior  therapy,  unre-
sectable GCToB due to potential involvement of
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adjacent critical structures, marginal resection
of GCToB without critical structure involvement
and other indications where the risk of recur-
rence was deemed high enough to warrant adju-
vant  or  definitive  radiotherapy.  An  additional
two patients received treatment for palliation.
The  most  common  indication  was  marginal
resection or residual tumor. Median radiation
dose was 50Gy (range 20 to 64.8Gy). Median
number of fractions was 25 (range 5 to 36 frac-
tions).  Median  dose  per  fraction  was  2Gy.
Median energy used was 6MV photons (range
1.25 to 25). For purposes of analysis, a local RT
field was defined as GTV plus a margin that was
less than or equal to 4 cm to the geometric edge
of the radiotherapy field.
Overall survival
Median  follow  up  was  8  years  (range  4
months  to  28.2  years).  Survival  information
was available on all 58 patients. Five-year over-
all survival was 94% (Figure 1). There were 5
deaths.  Cause  of  death  was  GCToB  in  2
patients, unknown in 1 patient. 
Disease free survival
Data was available for 54 patients. Five-year
disease free survival was 81% (Figure 2). Of the
10 patients with failures, 2 patients had distant
failures, 7 patients had local failures and one
patient had both local and distant failure.
Local control
Five year local control was 85% (Figure 3).
Of the 7 local failures, 3 failures were salvaged
successfully  with  surgery.  All  palliative
patients achieved symptom relief with radia-
tion. Eleven patients received chemotherapy.
Toxicity
Twenty-eight  patients  did  not  experience
any acute toxicity. Of the patients who experi-
enced toxicity, the most common acute toxici-
ty consisted of grade 1-2 skin changes. None of
the  patients  experienced  grade  3  or  higher
acute toxicity. Forty-six patients did not suffer
from  any  chronic  toxicity.  Of  patients  who
experienced  chronic  toxicity,  the  most  com-
mon  chronic  toxicity  consisted  of  skin
changes.  Two  patients  experienced  grade  3
toxicity. This consisted of grade 3 anovulatory
toxicity in one patient and grade 3 irregular
menses in the other patient. 
One patient developed an adenocarcinoma
of the uterine cervix as a possible secondary
malignancy in the field of radiation.
Prognostic factors
Univariate analysis did not reveal an associa-
tion  between  gender,  histology,  grade,  tumor
type, tumor location, tumor size, R1/R2 resec-
tion, radiation dose, or indication of radiation
(Table 3). There was a trend for improved 5 year
local  control  in  patients  less  than  30.8  years
when compared to the older group (96% com-
pared to 73%). There was improved disease free
survival and overall survival in the younger age
group  as  well  (96%  compared  to  65%)  and
(100% compared to 87%) respectively.
Discussion
Giant cell tumors of bone are locally aggres-
sive tumors with little tendency for metasta-
sis.1 The treatment of choice for these tumors,
historically,  has  been  surgical  resection.1 In
some cases, surgical resection can result in
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Table 1. Patient and tumor characteristics.
Characteristics Number of
patients (%)
Age
Age > 30.8 years 27 (49)
Age ≤ 30.8 years 28 (51)
Gender
Male  30 (55)
Female 25 (45)
Histology
92501 54 (93)
92503 4 (7)
Grade
Grade 1 9 (35)
Grade 2 13 (50)
Grade 3 4 (15)
Tumor Dimension
≥ 4cm 35 (78)
< 4 cm 10 (22)
Tumor Type prior to treatment
Primary 45 (78)
Recurrence 13 (22)
Primary bones involved
Appendicular 28 (48)
Axial 30 (52)
Primary bones involved by site
Lower limb long bone 23 (40)
Upper limb long bone 5 (9)
Lower limb small bone  0 (0)
Upper limb small bone 2 (3)
Craniofacial 2 (3)
Vertebral cervical 3 (5)
Vertebral thoracic/lumbar 8 (14)
Ribs/clavicle 1 (2)
Pelvic bones 10 (17)
Bones lumbar to pelvic 4 (7)
Most critical structures involved
None 26 (45)
Craniofacial 2 (3)
Brain/Spinal Cord 7 (12)
Sacral Plexus 13 (22)
Genitourinary tract 0 (0)
Joint 4 (7)
Neurovascular structure 2 (3)
Other 4 (7)
Table 2. Treatment and radiation therapy
characteristics.
Characteristic Number of
patients (%)
Extent of resection
R0 2 (3)
R1 30 (52)
R2 26 (45)
Indication for radiation
Marginal resection, residual tumor 33 (58)
Unresectable due to critical structures 13 (23)
Recurrence 9 (16)
Palliation 2 (4)
Radiation Dose
>50Gy 25 (43)
≤50 Gy 33 (57)
Radiation fractions
≥25 fractions 41 (71)
<25 fractions 17 (29)
Radiation delivery
Co-60 24 (44)
Linear Accelerator 22 (40)
Co-60 and Linear Accelerator 3 (5)
Roentgen therapy (X-ray) 2 (4)
Other 4 (7)
Field description
Local 48 (83)
Wide 10 (17)
Figure 1. Overall survival.
Figure 2. Disease free survival.
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severe impairment. In other cases, the site of
the tumor and the neighboring organs render
them  inoperable.3 However,  marginal  resec-
tions  result  in  a  high  rates  of  recurrence,
mostly  occurring  within  the  first  couple  of
years, justifying the use of adjuvant therapy.
GCToB are well responsive to radiation ther-
apy. Local control following adjuvant or primary
radiation therapy has ranged from 69% to 90%
according to recent studies.1,3,6,7,8,9
Our study reports a large published experi-
ence in the treatment of GCToB with radio-
therapy. The use of radiotherapy in this study
resulted in an 85% local control rate. We were
unable to identify any significant prognostic
factors except for age. Possible explanations
for  this  prognostic  factor  could  be  selection
bias and the choice for more aggressive sur-
gery in younger patients.
Other studies of GCToB have identified size
and location as having a significant impact on
local control. Miszczyk et al. identified tumor
size >4 cm as a negative prognostic factor for
local control.8 Caudell et al. and Feignberg et
al. identified recurrent tumors as a negative
prognostic factor for local control.3,10 Feignberg
et al. also identified a dose-effect relationship
with  radiation,  which  revealed  a  correlation
between doses of 40 Gy or less and a failure in
local control.3Our analysis did not find any cor-
relation with site, size or dose in terms of local
control  or  outcome.  This  could  possibly  be
explained  by  the  high  local  control  rate
achieved in our study and the inability to iden-
tify a poor prognostic group. Additionally, the
median  radiation  dose  utilized  was  50Gy.
Another possible explanation could be the het-
erogeneity of the patient population.
This study confirms the safety and efficacy
of radiation therapy as treatment for GCToB.
The median follow up for patients within this
study  was  8  years  (range  4  months  to  28.2
years). To date, none of the patients in this
study developed malignant transformation of
the GCToB or a radiation induced sarcoma. It
is important to note that one patient developed
an adenocarcinoma of the uterine cervix after
treatment of her GCToB. This can possibly be
attributed to a secondary malignancy from use
of radiation therapy. 
This is a multi-institutional study that was
retrospectively  performed.  The  limitations
include the retrospective nature, lack of uni-
form treatment and follow up as well as possi-
ble selection bias. However, despite these lim-
itations, our results in a fairly large group of
patients with this very uncommon disease con-
firm the findings of other studies in this rare
disease site with the use of radiation therapy.
It should be noted that the use of radiation
therapy  for  treatment  of  GCToB  has  signifi-
cantly improved the local control rates for this
rare  tumor  when  compared  to  local  control
rates for GCToB in which the sole treatment is
surgical resection. We suggest that the treat-
ment decision is made at a multidisciplinary
level to judge on an individual patient basis the
most appropriate treatment based on age, the
neighborhood of critical structures and surgi-
cal resectability. At our institution, we typically
offer radiation therapy to marginally resected,
unresectable or recurrent Giant Cell Tumors of
the Bone to a dose of 50Gy in 25 fractions,
although treatment may be customized based
on the patient’s age, volume of residual dis-
ease, and extent of unresected gross tumor.
The clinical treatment volume consists of the
preoperative gross tumor volume plus sites of
known or potential residual disease and poten-
tial areas of local extension.
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Table 3. Prognostic factors assessed on univariate analysis.
Prognostic Overall Disease free Local
factor survival survival Control
Age .03 .03 .09
Gender .69 .42 .28
Grade .14 .68 .29
Histology .21 .33 .42
Tumor type (primary vs.recurrence) .15 .45 .61
Tumor location (appendicular vs. axial) .94 .15 .49
Tumor size  .76 .87 .45
Extent of resection .90 .75 .89
Indication for radiation .15 .76 .78
Radiation dose .99 .44 .60
All numbers represent P values.